Developing Evidence-Based Sepsis Time Zero Criteria and Quality Metrics Using Electronic Health Record Data
使用电子健康记录数据制定循证脓毒症时间零标准和质量指标
基本信息
- 批准号:10613460
- 负责人:
- 金额:$ 47.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-03 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
PROJECT ABSTRACT
Sepsis is a leading cause of death. It is also a major driver of antibiotic utilization, in large part because
current guidelines and mandates compel clinicians to administer antibiotics immediately for all patients with
possible sepsis even though more than a third of patients initially suspected to have sepsis turn out to have
viral or non-infectious conditions. The Centers for Medicare & Medicaid Services (CMS) “SEP-1” measure, for
example, requires hospitals to give broad-spectrum antibiotics within 3 hours of to all patients with suspected
sepsis as well as measure lactate levels, draw blood cultures, and administer at least 30cc/kg of fluids for
hypotension. Newer guidelines are pushing for even faster antibiotic administration and bundle completion.
Aggressive, rigid, and reflexive sepsis care may therefore benefit some patients but also unnecessarily risks
promoting antibiotic resistance, drug adverse events, C.difficile infections, and fluid overload in others.
A major barrier to providing appropriate sepsis care to the right patients is our limited understanding of
which specific clinical presentations are most likely to benefit from immediate antibiotics and which can safely
be managed more conservatively. Similarly, we have imperfect understanding of which specific processes of
care are critical to optimize outcomes and which are not. To address these gaps, we need a better way to
define sepsis “time zero,” a concept that embodies both the criteria that should trigger immediate interventions
when infection is suspected and the point from which timeliness of care is measured. The current definition of
sepsis includes a heterogeneous mix of clinical signs, some of which are clearly urgent and some that may
tolerate more time for investigation before administering antibiotics. The problem is compounded by the fact
that SEP-1's time zero definition is subjective and labor-intensive to abstract, undermining its credibility and
utility for benchmarking hospitals' quality of care.
In this project, we propose to leverage detailed electronic health record data from millions of encounters
from 167 hospitals in two datasets to develop more evidence-based sepsis time zero criteria and quality
metrics. These goals are reflected our Specific Aims: 1) Develop evidence-based, objective, and electronically
computable definitions of sepsis time zero by using electronic health record data to identify the clinical signs
that are associated with higher mortality when antibiotics are delayed, 2) Systematically evaluate the
associations between each sepsis bundle component and mortality and compare the full bundle to simpler,
streamlined versions, and 3) Assess whether and how optimal treatment strategies differ for commonly
encountered and easily recognizable sepsis phenotypes based on infection site, comorbidities, and clinical
signs. This proposal directly addresses the antibiotic stewardship focus of AHRQ's HAI Prevention Portfolio
and AHRQ's mission to improve health care safety and quality by providing new insights into identifying and
treating sepsis, informing more rational antibiotic use, and facilitating better measurement of quality-of-care.
1
项目摘要
败血症是导致死亡的主要原因。它也是抗生素使用的主要驱动力,这在很大程度上是因为
目前的指南和要求迫使临床医生立即为所有患有
尽管超过三分之一的最初怀疑患有败血症的患者最终证实患有败血症,
病毒或非感染性疾病。医疗保险和医疗补助服务中心(CMS)“SEP-1”措施,
例如,要求医院在3小时内给予所有疑似患者广谱抗生素,
败血症以及测量乳酸水平,抽取血液培养物,并给予至少30 cc/kg的液体,
低血压更新的指南正在推动更快的抗生素管理和捆绑完成。
因此,积极、严格和反射性的脓毒症护理可能使一些患者受益,但也存在不必要的风险。
促进抗生素耐药性、药物不良事件、艰难梭菌感染和其他体液过多。
为正确的患者提供适当的脓毒症护理的一个主要障碍是我们对以下方面的了解有限:
哪些特定的临床表现最有可能从立即使用抗生素中获益,哪些可以安全地
更保守地管理。同样,我们也不完全了解哪些特定的过程,
护理对优化结果至关重要,而哪些不是。为了弥补这些差距,我们需要一种更好的方式,
将脓毒症定义为“时间零点”,这一概念既体现了应立即采取干预措施的标准,
当怀疑感染时,以及从何时开始衡量护理的及时性。目前的定义
脓毒症包括多种多样的临床体征,其中一些明显紧急,而另一些可能
在使用抗生素之前,需要更多的时间进行检查。问题因以下事实而变得复杂
SEP-1的时间零点定义是主观的和劳动密集型的抽象,破坏了它的可信度,
用于基准医院护理质量的实用程序。
在这个项目中,我们建议利用来自数百万次接触的详细电子健康记录数据,
来自167家医院的两个数据集,以制定更多基于证据的脓毒症零时标准和质量
指标.这些目标反映了我们的具体目标:1)发展基于证据的,客观的,电子化的
通过使用电子健康记录数据识别临床体征的脓毒症时间零点的可计算定义
当抗生素延迟使用时,与较高的死亡率相关,2)系统地评估
每个脓毒症束成分与死亡率之间的关联,并将完整束与简单束进行比较,
简化版本,以及3)评估最佳治疗策略是否以及如何与常见的
根据感染部位、合并症和临床表现,
信号装置.该提案直接涉及AHRQ HAI预防组合的抗生素管理重点
和AHRQ的使命,以提高医疗保健安全和质量,提供新的见解,以确定和
治疗败血症,告知更合理的抗生素使用,并促进更好地衡量护理质量。
1
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Clinical decision support improves blood culture collection before intravenous antibiotic administration in the emergency department.
临床决策支持可改善急诊室静脉注射抗生素之前的血培养收集。
- DOI:10.1093/jamia/ocac115
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Dutta,Sayon;McEvoy,DustinS;Rubins,DavidM;Dighe,AnandS;Filbin,MichaelR;Rhee,Chanu
- 通讯作者:Rhee,Chanu
Risk of Misleading Conclusions in Observational Studies of Time-to-Antibiotics and Mortality in Suspected Sepsis.
疑似脓毒症患者使用抗生素时间和死亡率的观察性研究中存在误导性结论的风险。
- DOI:10.1093/cid/ciad450
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Pak,TheodoreR;Young,Jessica;McKenna,CarolineS;Agan,Anna;DelloStritto,Laura;Filbin,MichaelR;Dutta,Sayon;Kadri,SameerS;Septimus,EdwardJ;Rhee,Chanu;Klompas,Michael
- 通讯作者:Klompas,Michael
Prospective External Validation of a Commercial Model Predicting the Likelihood of Inpatient Admission From the Emergency Department.
预测急诊科住院可能性的商业模型的前瞻性外部验证。
- DOI:10.1016/j.annemergmed.2022.11.012
- 发表时间:2023
- 期刊:
- 影响因子:6.2
- 作者:Dadabhoy,FarahZ;Driver,Lachlan;McEvoy,DustinS;Stevens,Ronelle;Rubins,David;Dutta,Sayon
- 通讯作者:Dutta,Sayon
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Klompas其他文献
Michael Klompas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Klompas', 18)}}的其他基金
Epicenter V: Harvard Pilgrim Health Care Institute Center for Excellence in HAI Surveillance and Prevention
Epicenter V:哈佛 Pilgrim 医疗保健研究所 HAI 监测和预防卓越中心
- 批准号:
10466726 - 财政年份:2021
- 资助金额:
$ 47.1万 - 项目类别:
Epicenter V: Harvard Pilgrim Health Care Institute Center for Excellence in HAI Surveillance and Prevention
Epicenter V:哈佛 Pilgrim 医疗保健研究所 HAI 监测和预防卓越中心
- 批准号:
10655385 - 财政年份:2021
- 资助金额:
$ 47.1万 - 项目类别:
Epicenter V: Harvard Pilgrim Health Care Institute Center for Excellence in HAI Surveillance and Prevention
Epicenter V:哈佛 Pilgrim 医疗保健研究所 HAI 监测和预防卓越中心
- 批准号:
10402234 - 财政年份:2021
- 资助金额:
$ 47.1万 - 项目类别:
Developing Evidence-Based Sepsis Time Zero Criteria and Quality Metrics Using Electronic Health Record Data
使用电子健康记录数据制定循证脓毒症时间零标准和质量指标
- 批准号:
10393530 - 财政年份:2020
- 资助金额:
$ 47.1万 - 项目类别:
Developing Evidence-Based Sepsis Time Zero Criteria and Quality Metrics Using Electronic Health Record Data
使用电子健康记录数据制定循证脓毒症时间零标准和质量指标
- 批准号:
10227896 - 财政年份:2020
- 资助金额:
$ 47.1万 - 项目类别:
Epicenters III: Translational Research to Prevent Healthcare Associated Infection
震中 III:预防医疗保健相关感染的转化研究
- 批准号:
8516902 - 财政年份:2012
- 资助金额:
$ 47.1万 - 项目类别:
相似海外基金
Listening to Patient Partners - From developing evidence-based tools for advancing meaningful patient engagement in research to now implementing them at an international organization for rheumatology research
倾听患者合作伙伴的意见 - 从开发基于证据的工具以促进患者有意义地参与研究,到现在在国际风湿病学研究组织中实施这些工具
- 批准号:
485116 - 财政年份:2023
- 资助金额:
$ 47.1万 - 项目类别:
Operating Grants
Towards climate-Positive cRopping: developing mOdel-based approaches to idenTify pathways, and EvidenCe benefiTs (PROTECT)
实现对气候有利的种植:开发基于模型的方法来确定路径和证据效益(保护)
- 批准号:
2894158 - 财政年份:2023
- 资助金额:
$ 47.1万 - 项目类别:
Studentship
Developing tools and guidelines to promote learning support based on educational data and evidence
开发工具和指南,以促进基于教育数据和证据的学习支持
- 批准号:
23H01002 - 财政年份:2023
- 资助金额:
$ 47.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Towards climate Positive baRley developing mOdel based approaches to idenTify pathways and EvidenCe benefiTs PROTECT
迈向气候积极的大麦开发基于模型的方法来确定途径和证据效益保护
- 批准号:
BB/Y513714/1 - 财政年份:2023
- 资助金额:
$ 47.1万 - 项目类别:
Training Grant
Developing the first evidence-based and stakeholder-supported definition of pain-related suffering: An essential foundation toward suffering-targeted pain management.
制定第一个基于证据和利益相关者支持的疼痛相关痛苦定义:针对痛苦的疼痛管理的重要基础。
- 批准号:
473871 - 财政年份:2022
- 资助金额:
$ 47.1万 - 项目类别:
Fellowship Programs
Tracking neurocognitive changes during evidence-based reading instruction in typically and atypically developing children
跟踪典型和非典型发育儿童的循证阅读教学期间的神经认知变化
- 批准号:
10698010 - 财政年份:2022
- 资助金额:
$ 47.1万 - 项目类别:
Building solutions to address drugs shortages in Canada: developing an evidence-based at-risk medicine list
制定解决加拿大药品短缺问题的解决方案:制定基于证据的高危药品清单
- 批准号:
475138 - 财政年份:2022
- 资助金额:
$ 47.1万 - 项目类别:
Operating Grants
Developing a Measure of College Student Buy-In to Evidence-Based Teaching Practices
制定大学生接受循证教学实践的衡量标准
- 批准号:
2216019 - 财政年份:2022
- 资助金额:
$ 47.1万 - 项目类别:
Standard Grant
Tracking neurocognitive changes during evidence-based reading instruction in typically and atypically developing children
跟踪典型和非典型发育儿童的循证阅读教学期间的神经认知变化
- 批准号:
10402459 - 财政年份:2022
- 资助金额:
$ 47.1万 - 项目类别:
Developing an Evidence-Based Child Suicide Prevention System Using Large Prospective Cohort Data
使用大型前瞻性队列数据开发基于证据的儿童自杀预防系统
- 批准号:
22H01087 - 财政年份:2022
- 资助金额:
$ 47.1万 - 项目类别:
Grant-in-Aid for Scientific Research (B)